Clinical trial · Interventional
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer
NCT05052723CI-TRIAL-00097542completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cabozantinib | Drug | Cabozantinib | ALIAS |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cabozantinib and pembrolizumab
- interventionNames
- Drug: Cabozantinib
- Drug: Pembrolizumab
Primary outcomes (1)
- measure
- Progression-free Survival
- timeFrame
- 1 year
- description
- Progress-free survival in participants, defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever comes first.
Secondary outcomes (4)
- measure
- Number of Participants With Response to Therapy
- timeFrame
- 1 year
- description
- The proportion of participants with overall response to therapy via imaging; Overall Response Rate (%) = (Number of patients achieving Complete responses + Number of patients achieving partial responses / Total Number of patients) × 100
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of pancreatic ductal adenocarcinoma * Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies * Patients must have adequate organ function Exclusion Criteria: * Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation * Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention * Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation * Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy * Clinically significant cardiovascular disease * Uncontrolled hypertension * Inability to swallow tablets
References
Publications (1)
- DERIVEDMcDonald HG, Cassim EB, Harper MM, Burke EE, Marcinkowski EF, Cavnar MJ, Pandalai PK, Kim J. The Development of Investigator-Initiated Clinical Trials in Surgical Oncology. Surg Oncol Clin N Am. 2023 Jan;32(1):13-25. doi: 10.1016/j.soc.2022.07.003. Epub 2022 Nov 3. PMID 36410913